APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-angiogenic Ophthalmic Agent

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Anti-angiogenic Ophthalmic Agent Industry Growth and Trends Forecast to 2032

22 December 2025126 pages

Choose your research edition.

Industry ResearchAnti-angiogenic Ophthalmic Agent Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-angiogenic Ophthalmic Agent Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Anti-angiogenic Ophthalmic Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-angiogenic Ophthalmic Agent Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-angiogenic Ophthalmic Agent Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Anti-angiogenic Ophthalmic Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Anti-angiogenic Ophthalmic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Anti-angiogenic Ophthalmic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-angiogenic Ophthalmic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anti-angiogenic Ophthalmic Agent include Sun Pharma, Johnson & Johnson, Novartis AG, Gilead Sciences, Inc., Pfizer, Daiichi Sankyo, Bayer AG, The Geuder Group, MORCHER GmbH and Shanghai Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Anti-angiogenic Ophthalmic Agent market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Anti-angiogenic Ophthalmic Agent market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti-angiogenic Ophthalmic Agent market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti-angiogenic Ophthalmic Agent.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Anti-angiogenic Ophthalmic Agent market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Anti-angiogenic Ophthalmic Agent Market by Company

Sun Pharma

Johnson & Johnson

Novartis AG

Gilead Sciences, Inc.

Pfizer

Daiichi Sankyo

Bayer AG

The Geuder Group, MORCHER GmbH

Shanghai Pharmaceuticals

Santen Pharmaceutical Co., Ltd.

Regeneron Pharmaceuticals, Inc.

Otsuka Pharmaceutical Co. Ltd

Novamedika

Medicom Health care

Implant ophthalmic products GmbH

Genentech, Inc.

Eyetech Inc.

ERC Labs

Becton, Dickinson and Company

Allergan plc

Anti-angiogenic Ophthalmic Agent Segment by Type

Diabetic Retinopathy

Myopic Choroidal Neovascularization

Macular Edema

Macular Degeneration

Anti-angiogenic Ophthalmic Agent Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Anti-angiogenic Ophthalmic Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-angiogenic Ophthalmic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-angiogenic Ophthalmic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-angiogenic Ophthalmic Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anti-angiogenic Ophthalmic Agent manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Anti-angiogenic Ophthalmic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Diabetic Retinopathy Table 2. Major Company of Myopic Choroidal Neovascularization Table 3. Major Company of Macular Edema Table 4. Major Company of Macular Degeneration Table 5. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 7. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Type (2021-2026) Table 8. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (US$ Million) Table 9. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Type (2021-2026) Table 10. Global Anti-angiogenic Ophthalmic Agent Price by Type (2021-2026) & (US$/unit) Table 11. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2027-2032) & (k units) Table 12. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Type (2027-2032) Table 13. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2027-2032) & (US$ Million) Table 14. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Type (2027-2032) Table 15. Global Anti-angiogenic Ophthalmic Agent Price by Type (2027-2032) & (US$/unit) Table 16. North America Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 17. North America Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 19. Europe Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 23. Latin America Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (US$ Million) Table 26. Anti-angiogenic Ophthalmic Agent Industry Trends Table 27. Anti-angiogenic Ophthalmic Agent Industry Drivers Table 28. Anti-angiogenic Ophthalmic Agent Industry Opportunities and Challenges Table 29. Anti-angiogenic Ophthalmic Agent Industry Restraints Table 30. Global Anti-angiogenic Ophthalmic Agent Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Company (2021-2026) Table 32. Global Anti-angiogenic Ophthalmic Agent Sales by Company (2021-2026) & (k units) Table 33. Global Anti-angiogenic Ophthalmic Agent Sales Share by Company (2021-2026) Table 34. Global Anti-angiogenic Ophthalmic Agent Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Anti-angiogenic Ophthalmic Agent Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Anti-angiogenic Ophthalmic Agent Major Company Production Sites and Headquarters Table 37. Global Anti-angiogenic Ophthalmic Agent Company, Product Type & Application Table 38. Global Anti-angiogenic Ophthalmic Agent Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Anti-angiogenic Ophthalmic Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Anti-angiogenic Ophthalmic Agent Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2021-2026) & (k units) Table 43. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Region (2021-2026) Table 44. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2021-2026) & (US$ Million) Table 45. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Region (2021-2026) Table 46. Global Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2027-2032) & (k units) Table 48. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Region (2027-2032) Table 49. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2027-2032) & (US$ Million) Table 50. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Region (2027-2032) Table 51. Global Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 54. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Application (2021-2026) Table 55. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (US$ Million) Table 56. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Application (2021-2026) Table 57. Global Anti-angiogenic Ophthalmic Agent Price by Application (2021-2026) & (US$/unit) Table 58. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2027-2032) & (k units) Table 59. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Application (2027-2032) Table 60. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2027-2032) & (US$ Million) Table 61. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Application (2027-2032) Table 62. Global Anti-angiogenic Ophthalmic Agent Price by Application (2027-2032) & (US$/unit) Table 63. North America Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 64. North America Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 66. Europe Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 70. Latin America Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (US$ Million) Table 73. Sun Pharma Company Information Table 74. Sun Pharma Business Overview Table 75. Sun Pharma Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Sun Pharma Anti-angiogenic Ophthalmic Agent Product Portfolio Table 77. Sun Pharma Recent Development Table 78. Johnson & Johnson Company Information Table 79. Johnson & Johnson Business Overview Table 80. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Portfolio Table 82. Johnson & Johnson Recent Development Table 83. Novartis AG Company Information Table 84. Novartis AG Business Overview Table 85. Novartis AG Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Novartis AG Anti-angiogenic Ophthalmic Agent Product Portfolio Table 87. Novartis AG Recent Development Table 88. Gilead Sciences, Inc. Company Information Table 89. Gilead Sciences, Inc. Business Overview Table 90. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 92. Gilead Sciences, Inc. Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Pfizer Anti-angiogenic Ophthalmic Agent Product Portfolio Table 97. Pfizer Recent Development Table 98. Daiichi Sankyo Company Information Table 99. Daiichi Sankyo Business Overview Table 100. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Portfolio Table 102. Daiichi Sankyo Recent Development Table 103. Bayer AG Company Information Table 104. Bayer AG Business Overview Table 105. Bayer AG Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Bayer AG Anti-angiogenic Ophthalmic Agent Product Portfolio Table 107. Bayer AG Recent Development Table 108. The Geuder Group, MORCHER GmbH Company Information Table 109. The Geuder Group, MORCHER GmbH Business Overview Table 110. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio Table 112. The Geuder Group, MORCHER GmbH Recent Development Table 113. Shanghai Pharmaceuticals Company Information Table 114. Shanghai Pharmaceuticals Business Overview Table 115. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Portfolio Table 117. Shanghai Pharmaceuticals Recent Development Table 118. Santen Pharmaceutical Co., Ltd. Company Information Table 119. Santen Pharmaceutical Co., Ltd. Business Overview Table 120. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 122. Santen Pharmaceutical Co., Ltd. Recent Development Table 123. Regeneron Pharmaceuticals, Inc. Company Information Table 124. Regeneron Pharmaceuticals, Inc. Business Overview Table 125. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 127. Regeneron Pharmaceuticals, Inc. Recent Development Table 128. Otsuka Pharmaceutical Co. Ltd Company Information Table 129. Otsuka Pharmaceutical Co. Ltd Business Overview Table 130. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Portfolio Table 132. Otsuka Pharmaceutical Co. Ltd Recent Development Table 133. Novamedika Company Information Table 134. Novamedika Business Overview Table 135. Novamedika Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Novamedika Anti-angiogenic Ophthalmic Agent Product Portfolio Table 137. Novamedika Recent Development Table 138. Medicom Health care Company Information Table 139. Medicom Health care Business Overview Table 140. Medicom Health care Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Medicom Health care Anti-angiogenic Ophthalmic Agent Product Portfolio Table 142. Medicom Health care Recent Development Table 143. Implant ophthalmic products GmbH Company Information Table 144. Implant ophthalmic products GmbH Business Overview Table 145. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 146. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio Table 147. Implant ophthalmic products GmbH Recent Development Table 148. Genentech, Inc. Company Information Table 149. Genentech, Inc. Business Overview Table 150. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 151. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 152. Genentech, Inc. Recent Development Table 153. Eyetech Inc. Company Information Table 154. Eyetech Inc. Business Overview Table 155. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 156. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 157. Eyetech Inc. Recent Development Table 158. ERC Labs Company Information Table 159. ERC Labs Business Overview Table 160. ERC Labs Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 161. ERC Labs Anti-angiogenic Ophthalmic Agent Product Portfolio Table 162. ERC Labs Recent Development Table 163. Becton, Dickinson and Company Company Information Table 164. Becton, Dickinson and Company Business Overview Table 165. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 166. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Portfolio Table 167. Becton, Dickinson and Company Recent Development Table 168. Allergan plc Company Information Table 169. Allergan plc Business Overview Table 170. Allergan plc Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 171. Allergan plc Anti-angiogenic Ophthalmic Agent Product Portfolio Table 172. Allergan plc Recent Development Table 173. North America Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 174. North America Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 175. North America Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2026) Table 176. North America Anti-angiogenic Ophthalmic Agent Sales Forecast by Country (2027-2032) & (k units) Table 177. North America Anti-angiogenic Ophthalmic Agent Sales Market Share Forecast by Country (2027-2032) Table 178. North America Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. North America Anti-angiogenic Ophthalmic Agent Market Size by Country (2021-2026) & (US$ Million) Table 180. North America Anti-angiogenic Ophthalmic Agent Market Share by Country (2021-2026) Table 181. North America Anti-angiogenic Ophthalmic Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. North America Anti-angiogenic Ophthalmic Agent Market Share Forecast by Country (2027-2032) Table 183. Europe Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 184. Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 185. Europe Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2026) Table 186. Europe Anti-angiogenic Ophthalmic Agent Sales Forecast by Country (2027-2032) & (k units) Table 187. Europe Anti-angiogenic Ophthalmic Agent Sales Market Share Forecast by Country (2027-2032) Table 188. Europe Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Europe Anti-angiogenic Ophthalmic Agent Market Size by Country (2021-2026) & (US$ Million) Table 190. Europe Anti-angiogenic Ophthalmic Agent Market Share by Country (2021-2026) Table 191. Europe Anti-angiogenic Ophthalmic Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Europe Anti-angiogenic Ophthalmic Agent Market Share Forecast by Country (2027-2032) Table 193. Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 194. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 195. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2026) Table 196. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Forecast by Country (2027-2032) & (k units) Table 197. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Market Share Forecast by Country (2027-2032) Table 198. Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 199. Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Size by Country (2021-2026) & (US$ Million) Table 200. Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Share by Country (2021-2026) Table 201. Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 202. Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Share Forecast by Country (2027-2032) Table 203. Latin America Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 204. Latin America Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 205. Latin America Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2026) Table 206. Latin America Anti-angiogenic Ophthalmic Agent Sales Forecast by Country (2027-2032) & (k units) Table 207. Latin America Anti-angiogenic Ophthalmic Agent Sales Market Share Forecast by Country (2027-2032) Table 208. Latin America Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 209. Latin America Anti-angiogenic Ophthalmic Agent Market Size by Country (2021-2026) & (US$ Million) Table 210. Latin America Anti-angiogenic Ophthalmic Agent Market Share by Country (2021-2026) Table 211. Latin America Anti-angiogenic Ophthalmic Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 212. Latin America Anti-angiogenic Ophthalmic Agent Market Share Forecast by Country (2027-2032) Table 213. Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 214. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 215. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2026) Table 216. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Forecast by Country (2027-2032) & (k units) Table 217. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Market Share Forecast by Country (2027-2032) Table 218. Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 219. Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Size by Country (2021-2026) & (US$ Million) Table 220. Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Share by Country (2021-2026) Table 221. Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Size Forecast by Country (2027-2032) & (US$ Million) Table 222. Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Share Forecast by Country (2027-2032) Table 223. Key Raw Materials Table 224. Raw Materials Key Suppliers Table 225. Anti-angiogenic Ophthalmic Agent Distributors List Table 226. Anti-angiogenic Ophthalmic Agent Customers List Table 227. Research Programs/Design for This Report Table 228. Authors List of This Report Table 229. Secondary Sources Table 230. Primary Sources List of Figures Figure 1. Anti-angiogenic Ophthalmic Agent Image Figure 2. Global Anti-angiogenic Ophthalmic Agent Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-angiogenic Ophthalmic Agent Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-angiogenic Ophthalmic Agent Sales (2021-2032) & (k units) Figure 5. Diabetic Retinopathy Image Figure 6. Global Diabetic Retinopathy Sales YoY Growth (2021-2032) & (k units) Figure 7. Myopic Choroidal Neovascularization Image Figure 8. Global Myopic Choroidal Neovascularization Sales YoY Growth (2021-2032) & (k units) Figure 9. Macular Edema Image Figure 10. Global Macular Edema Sales YoY Growth (2021-2032) & (k units) Figure 11. Macular Degeneration Image Figure 12. Global Macular Degeneration Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Anti-angiogenic Ophthalmic Agent Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Anti-angiogenic Ophthalmic Agent Market Share by Type 2025 VS 2032 Figure 15. North America Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Type in 2025 Figure 16. North America Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Type in 2025 Figure 17. Europe Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Type in 2025 Figure 18. Europe Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Type in 2025 Figure 21. Latin America Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Anti-angiogenic Ophthalmic Agent Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital Pharmacies Image Figure 28. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 29. Online Pharmacies Image Figure 30. Global Online Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 31. Retail Pharmacies Image Figure 32. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 33. Global Anti-angiogenic Ophthalmic Agent Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Anti-angiogenic Ophthalmic Agent Market Share by Application 2025 VS 2032 Figure 35. North America Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Application in 2025 Figure 36. North America Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Application in 2025 Figure 37. Europe Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Application in 2025 Figure 38. Europe Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Application in 2025 Figure 41. Latin America Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Application in 2025 Figure 45. North America Anti-angiogenic Ophthalmic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America Anti-angiogenic Ophthalmic Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Anti-angiogenic Ophthalmic Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Anti-angiogenic Ophthalmic Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Anti-angiogenic Ophthalmic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe Anti-angiogenic Ophthalmic Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Anti-angiogenic Ophthalmic Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Anti-angiogenic Ophthalmic Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Anti-angiogenic Ophthalmic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America Anti-angiogenic Ophthalmic Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Anti-angiogenic Ophthalmic Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Anti-angiogenic Ophthalmic Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Anti-angiogenic Ophthalmic Agent Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Anti-angiogenic Ophthalmic Agent Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Diabetic Retinopathy
  • Myopic Choroidal Neovascularization
  • Macular Edema
  • Macular Degeneration
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Sun Pharma
  • Johnson & Johnson
  • Novartis AG
  • Gilead Sciences, Inc.
  • Pfizer
  • Daiichi Sankyo
  • Bayer AG
  • The Geuder Group, MORCHER GmbH
  • Shanghai Pharmaceuticals
  • Santen Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co. Ltd
  • Novamedika
  • Medicom Health care
  • Implant ophthalmic products GmbH
  • Genentech, Inc.
  • Eyetech Inc.
  • ERC Labs
  • Becton, Dickinson and Company
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-angiogenic Ophthalmic Agent Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Anti-angiogenic Ophthalmic Agent Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Anti-angiogenic Ophthalmic Agent Market by Type
  6. 1.3.1 Diabetic Retinopathy
  7. 1.3.2 Myopic Choroidal Neovascularization
  8. 1.3.3 Macular Edema
  9. 1.3.4 Macular Degeneration
  10. 1.4 Global Anti-angiogenic Ophthalmic Agent Market Size by Type
  11. 1.4.1 Global Anti-angiogenic Ophthalmic Agent Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Anti-angiogenic Ophthalmic Agent Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Anti-angiogenic Ophthalmic Agent Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Anti-angiogenic Ophthalmic Agent Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Anti-angiogenic Ophthalmic Agent Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Anti-angiogenic Ophthalmic Agent Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Anti-angiogenic Ophthalmic Agent Industry Trends
  2. 2.2 Anti-angiogenic Ophthalmic Agent Industry Drivers
  3. 2.3 Anti-angiogenic Ophthalmic Agent Industry Opportunities and Challenges
  4. 2.4 Anti-angiogenic Ophthalmic Agent Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Anti-angiogenic Ophthalmic Agent Revenue (2021-2026)
  2. 3.2 Global Top Players by Anti-angiogenic Ophthalmic Agent Sales (2021-2026)
  3. 3.3 Global Top Players by Anti-angiogenic Ophthalmic Agent Price (2021-2026)
  4. 3.4 Global Anti-angiogenic Ophthalmic Agent Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anti-angiogenic Ophthalmic Agent Major Company Production Sites & Headquarters
  6. 3.6 Global Anti-angiogenic Ophthalmic Agent Company, Product Type & Application
  7. 3.7 Global Anti-angiogenic Ophthalmic Agent Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anti-angiogenic Ophthalmic Agent Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anti-angiogenic Ophthalmic Agent Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anti-angiogenic Ophthalmic Agent Tier 1, Tier 2, and Tier 3
4 Anti-angiogenic Ophthalmic Agent Regional Status and Outlook
  1. 4.1 Global Anti-angiogenic Ophthalmic Agent Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Anti-angiogenic Ophthalmic Agent Historic Market Size by Region
  3. 4.2.1 Global Anti-angiogenic Ophthalmic Agent Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Anti-angiogenic Ophthalmic Agent Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Anti-angiogenic Ophthalmic Agent Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Anti-angiogenic Ophthalmic Agent Forecasted Market Size by Region
  7. 4.3.1 Global Anti-angiogenic Ophthalmic Agent Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Anti-angiogenic Ophthalmic Agent Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Anti-angiogenic Ophthalmic Agent Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Anti-angiogenic Ophthalmic Agent by Application
  1. 5.1 Anti-angiogenic Ophthalmic Agent Market by Application
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Anti-angiogenic Ophthalmic Agent Market Size by Application
  6. 5.2.1 Global Anti-angiogenic Ophthalmic Agent Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Anti-angiogenic Ophthalmic Agent Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Anti-angiogenic Ophthalmic Agent Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Anti-angiogenic Ophthalmic Agent Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Anti-angiogenic Ophthalmic Agent Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Anti-angiogenic Ophthalmic Agent Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sun Pharma
  2. 6.1.1 Sun Pharma Company Information
  3. 6.1.2 Sun Pharma Business Overview
  4. 6.1.3 Sun Pharma Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sun Pharma Anti-angiogenic Ophthalmic Agent Product Portfolio
  6. 6.1.5 Sun Pharma Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Novartis AG
  14. 6.3.1 Novartis AG Company Information
  15. 6.3.2 Novartis AG Business Overview
  16. 6.3.3 Novartis AG Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novartis AG Anti-angiogenic Ophthalmic Agent Product Portfolio
  18. 6.3.5 Novartis AG Recent Developments
  19. 6.4 Gilead Sciences, Inc.
  20. 6.4.1 Gilead Sciences, Inc. Company Information
  21. 6.4.2 Gilead Sciences, Inc. Business Overview
  22. 6.4.3 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  24. 6.4.5 Gilead Sciences, Inc. Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Pfizer Anti-angiogenic Ophthalmic Agent Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 Daiichi Sankyo
  32. 6.6.1 Daiichi Sankyo Company Information
  33. 6.6.2 Daiichi Sankyo Business Overview
  34. 6.6.3 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Portfolio
  36. 6.6.5 Daiichi Sankyo Recent Developments
  37. 6.7 Bayer AG
  38. 6.7.1 Bayer AG Company Information
  39. 6.7.2 Bayer AG Business Overview
  40. 6.7.3 Bayer AG Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Bayer AG Anti-angiogenic Ophthalmic Agent Product Portfolio
  42. 6.7.5 Bayer AG Recent Developments
  43. 6.8 The Geuder Group, MORCHER GmbH
  44. 6.8.1 The Geuder Group, MORCHER GmbH Company Information
  45. 6.8.2 The Geuder Group, MORCHER GmbH Business Overview
  46. 6.8.3 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio
  48. 6.8.5 The Geuder Group, MORCHER GmbH Recent Developments
  49. 6.9 Shanghai Pharmaceuticals
  50. 6.9.1 Shanghai Pharmaceuticals Company Information
  51. 6.9.2 Shanghai Pharmaceuticals Business Overview
  52. 6.9.3 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Portfolio
  54. 6.9.5 Shanghai Pharmaceuticals Recent Developments
  55. 6.10 Santen Pharmaceutical Co., Ltd.
  56. 6.10.1 Santen Pharmaceutical Co., Ltd. Company Information
  57. 6.10.2 Santen Pharmaceutical Co., Ltd. Business Overview
  58. 6.10.3 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Portfolio
  60. 6.10.5 Santen Pharmaceutical Co., Ltd. Recent Developments
  61. 6.11 Regeneron Pharmaceuticals, Inc.
  62. 6.11.1 Regeneron Pharmaceuticals, Inc. Company Information
  63. 6.11.2 Regeneron Pharmaceuticals, Inc. Business Overview
  64. 6.11.3 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  66. 6.11.5 Regeneron Pharmaceuticals, Inc. Recent Developments
  67. 6.12 Otsuka Pharmaceutical Co. Ltd
  68. 6.12.1 Otsuka Pharmaceutical Co. Ltd Company Information
  69. 6.12.2 Otsuka Pharmaceutical Co. Ltd Business Overview
  70. 6.12.3 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Portfolio
  72. 6.12.5 Otsuka Pharmaceutical Co. Ltd Recent Developments
  73. 6.13 Novamedika
  74. 6.13.1 Novamedika Company Information
  75. 6.13.2 Novamedika Business Overview
  76. 6.13.3 Novamedika Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Novamedika Anti-angiogenic Ophthalmic Agent Product Portfolio
  78. 6.13.5 Novamedika Recent Developments
  79. 6.14 Medicom Health care
  80. 6.14.1 Medicom Health care Company Information
  81. 6.14.2 Medicom Health care Business Overview
  82. 6.14.3 Medicom Health care Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Medicom Health care Anti-angiogenic Ophthalmic Agent Product Portfolio
  84. 6.14.5 Medicom Health care Recent Developments
  85. 6.15 Implant ophthalmic products GmbH
  86. 6.15.1 Implant ophthalmic products GmbH Company Information
  87. 6.15.2 Implant ophthalmic products GmbH Business Overview
  88. 6.15.3 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio
  90. 6.15.5 Implant ophthalmic products GmbH Recent Developments
  91. 6.16 Genentech, Inc.
  92. 6.16.1 Genentech, Inc. Company Information
  93. 6.16.2 Genentech, Inc. Business Overview
  94. 6.16.3 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  96. 6.16.5 Genentech, Inc. Recent Developments
  97. 6.17 Eyetech Inc.
  98. 6.17.1 Eyetech Inc. Company Information
  99. 6.17.2 Eyetech Inc. Business Overview
  100. 6.17.3 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  102. 6.17.5 Eyetech Inc. Recent Developments
  103. 6.18 ERC Labs
  104. 6.18.1 ERC Labs Company Information
  105. 6.18.2 ERC Labs Business Overview
  106. 6.18.3 ERC Labs Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 ERC Labs Anti-angiogenic Ophthalmic Agent Product Portfolio
  108. 6.18.5 ERC Labs Recent Developments
  109. 6.19 Becton, Dickinson and Company
  110. 6.19.1 Becton, Dickinson and Company Company Information
  111. 6.19.2 Becton, Dickinson and Company Business Overview
  112. 6.19.3 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Portfolio
  114. 6.19.5 Becton, Dickinson and Company Recent Developments
  115. 6.20 Allergan plc
  116. 6.20.1 Allergan plc Company Information
  117. 6.20.2 Allergan plc Business Overview
  118. 6.20.3 Allergan plc Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Allergan plc Anti-angiogenic Ophthalmic Agent Product Portfolio
  120. 6.20.5 Allergan plc Recent Developments
7 North America by Country
  1. 7.1 North America Anti-angiogenic Ophthalmic Agent Sales by Country
  2. 7.1.1 North America Anti-angiogenic Ophthalmic Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026)
  4. 7.1.3 North America Anti-angiogenic Ophthalmic Agent Sales Forecast by Country (2027-2032)
  5. 7.2 North America Anti-angiogenic Ophthalmic Agent Market Size by Country
  6. 7.2.1 North America Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Anti-angiogenic Ophthalmic Agent Market Size by Country (2021-2026)
  8. 7.2.3 North America Anti-angiogenic Ophthalmic Agent Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Anti-angiogenic Ophthalmic Agent Sales by Country
  2. 8.1.1 Europe Anti-angiogenic Ophthalmic Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026)
  4. 8.1.3 Europe Anti-angiogenic Ophthalmic Agent Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Anti-angiogenic Ophthalmic Agent Market Size by Country
  6. 8.2.1 Europe Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Anti-angiogenic Ophthalmic Agent Market Size by Country (2021-2026)
  8. 8.2.3 Europe Anti-angiogenic Ophthalmic Agent Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales by Country
  2. 9.1.1 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Size by Country
  6. 9.2.1 Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Anti-angiogenic Ophthalmic Agent Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Anti-angiogenic Ophthalmic Agent Sales by Country
  2. 10.1.1 South America Anti-angiogenic Ophthalmic Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026)
  4. 10.1.3 South America Anti-angiogenic Ophthalmic Agent Sales Forecast by Country (2027-2032)
  5. 10.2 South America Anti-angiogenic Ophthalmic Agent Market Size by Country
  6. 10.2.1 South America Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Anti-angiogenic Ophthalmic Agent Market Size by Country (2021-2026)
  8. 10.2.3 South America Anti-angiogenic Ophthalmic Agent Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Country
  2. 11.1.1 Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Size by Country
  6. 11.2.1 Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Anti-angiogenic Ophthalmic Agent Value Chain Analysis
  2. 12.1.1 Anti-angiogenic Ophthalmic Agent Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Anti-angiogenic Ophthalmic Agent Production Mode & Process
  7. 12.2 Anti-angiogenic Ophthalmic Agent Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Anti-angiogenic Ophthalmic Agent Distributors
  10. 12.2.3 Anti-angiogenic Ophthalmic Agent Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst